Breaking News Instant updates and real-time market news.

MYGN

Myriad Genetics

$21.35

0.165 (0.78%)

, TSRO

Tesaro

$99.26

-0.63 (-0.63%)

06:57
10/10/16
10/10
06:57
10/10/16
06:57

TESARO data suggest Myriad test not necessary, says Piper Jaffray

Piper Jaffray analyst William Quirk points out that data over the weekend from TESARO (TSRO), Myriad Genetics' (MYGN) companion diagnostic partner, suggest niraparib works in all-comers, making Myriad's test not necessary. Myriad shares may be down physiologically, Quirk tells investors in a research note partially titled "When A Partnership Produces Mixed Results." The analyst, however, believes niraparib is not clinically significant in HRD negative patients and that Myriad's test will be included on the drug label. He keeps a Neutral rating on shares of Myriad. Ladenburg Thalmann this morning downgraded the stock to Neutral.

MYGN

Myriad Genetics

$21.35

0.165 (0.78%)

TSRO

Tesaro

$99.26

-0.63 (-0.63%)

  • 10

    Oct

  • 06

    Nov

  • 11

    Jan

MYGN Myriad Genetics
$21.35

0.165 (0.78%)

08/10/16
08/10/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. SunPower (SPWR) downgraded to Neutral from Overweight at JPMorgan, to Perform from Outperform at Oppenheimer, to Hold from Buy at Deutsche Bank, to Neutral from Buy at Janney Capital, to Neutral from Outperform at Credit Suisse, and to Market Perform from Outperform at Avondale. 2. Noble Corp. (NE) downgraded to Sell from Hold at Argus with analyst David Coleman saying the company is being hurt by declining offshore drilling activity, lower fleet utilization and falling day rates. 3. Wayfair (W) downgraded to Neutral from Buy at Goldman and to Neutral from Buy at BofA/Merrill. 4. Buffalo Wild Wings (BWLD) downgraded to Market Perform from Outperform at Raymond James with analyst Brian Vaccaro saying shares are fairly valued in the context of below average comp visibility in the near-term and largely discount the benefits of near-term potential activist proposals. 5. Myriad Genetics (MYGN) downgraded to Equal Weight from Overweight at Barclays, to Neutral from Overweight at Piper Jaffray, to Market Perform from Outperform at Wells Fargo, and to Hold from Buy at Gabelli. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/11/16
SPHN
08/11/16
NO CHANGE
Target $30
SPHN
Overweight
Myriad Genetics price target lowered to $30 from $47 at Stephens
Stephens analyst Drew Jones lowered his price target for Myriad Genetics to $30 from $47 after the company missed Q4 expectations slightly and issued "disappointing" 2017 guide. The analyst sees hereditary cancer as the "primary culprit," with sales turnover blamed for volume weakness. Further, Jones believes the lack of visibility into this weakness has created an overhang that will not be solved with "one decent quarter." He reiterates an Overweight rating on the shares.
08/29/16
BOFA
08/29/16
NO CHANGE
BOFA
Myriad Genetics loses BCBS of Nevada contract to LabCorp, says BofA/Merrill
Analysts at BofA Merrill Lynch noted that Myriad Genetics (MYGN) has lost an in-network contract with Blue Cross Blue Shield of Nevada to LabCorp (LH) and the firm expects Myriad shares to trade down following the news. The firm sees the potential for a continuation of this trend across other BCBS systems in other states.
10/10/16
LTCO
10/10/16
DOWNGRADE
Target $16
LTCO
Sell
Myriad Genetics downgraded to Sell from Neutral at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter downgraded Myriad Genetics (MYGN) to Sell citing a "significant and unexpected deterioration" in outlook for the company's companion diagnostic franchise. The analyst expects a lower growth outlook to drive "significant P/E multiple compression." Tesaro (TSRO) presented data this weekend that suggested its PARP inhibitor niraparib was active in a maintenance setting for recurrent ovarian cancer in patients with either positive or negative HRD scores. The analyst had expected the drug to benefit only HRD positive patients. As such, the use of niraparib will not require HRD testing, DeGeeter tells investors in a research note. The analyst has a $16 price target for the shares.
TSRO Tesaro
$99.26

-0.63 (-0.63%)

10/10/16
SBSH
10/10/16
NO CHANGE
Target $125
SBSH
Buy
Citi sees broad label for TESARO, ups target to $125
Citi analyst Robyn Karnauskas raised her price target for TESARO to $125 from $120 after the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. The stock in pre-market trading is up 4% to $103.10. Niraparib maintenance helps all ovarian cancer patients, making a broad label likely, Karnauskas tells investors in a research note. The analyst keeps a Buy rating on TESARO shares.
10/10/16
BOFA
10/10/16
UPGRADE
BOFA
Buy
TESARO upgraded to Buy from Neutral at BofA/Merrill
10/10/16
BOFA
10/10/16
UPGRADE
Target $123
BOFA
Buy
TESARO upgraded to Buy following NOVA study data at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad upgraded TESARO to Buy and raised its price target to $123 from $97 after the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. Ahmad said the data removes a key overhang of efficacy outside of BRCA mutations and sees a clearer path towards approval and a favorable label.

TODAY'S FREE FLY STORIES

ESRX

Express Scripts

$61.00

-1.01 (-1.63%)

14:25
09/20/17
09/20
14:25
09/20/17
14:25
Options
Express Scripts call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 25

    Oct

14:25
09/20/17
09/20
14:25
09/20/17
14:25
General news
FX Action: The dollar rose, then fell, then rose again »

FX Action: The dollar…

14:25
09/20/17
09/20
14:25
09/20/17
14:25
Conference/Events
Federal Reserve Chairperson Yellen holds a press conference »

Following a quarterly…

CVS

CVS Health

$81.68

-1.42 (-1.71%)

, WBA

Walgreens Boots Alliance

$81.21

-1.39 (-1.68%)

14:20
09/20/17
09/20
14:20
09/20/17
14:20
Hot Stocks
Pharmacies drop after Leerink says Amazon talking to PBMs »

After speaking with…

CVS

CVS Health

$81.68

-1.42 (-1.71%)

WBA

Walgreens Boots Alliance

$81.21

-1.39 (-1.68%)

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

ESRX

Express Scripts

$61.00

-1.01 (-1.63%)

ABC

AmerisourceBergen

$78.74

-0.54 (-0.68%)

CAH

Cardinal Health

$66.44

0.179 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 17

    Oct

  • 22

    Oct

  • 25

    Oct

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

14:20
09/20/17
09/20
14:20
09/20/17
14:20
Recommendations
Alnylam analyst commentary  »

Alnylam price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

14:20
09/20/17
09/20
14:20
09/20/17
14:20
General news
Treasury Action: yields knee-jerked higher »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

14:17
09/20/17
09/20
14:17
09/20/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
09/20/17
09/20
14:16
09/20/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWKS

Skyworks

$107.93

0.44 (0.41%)

14:15
09/20/17
09/20
14:15
09/20/17
14:15
Options
Skyworks put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

14:15
09/20/17
09/20
14:15
09/20/17
14:15
General news
FOMC announced balance sheet runoff in October and left rates unchanged »

FOMC announced balance…

14:15
09/20/17
09/20
14:15
09/20/17
14:15
General news
Breaking General news story  »

Fed Chair Press…

SPY

SPDR S&P 500 ETF Trust

$249.89

-0.08 (-0.03%)

, SPX

S&P 500

14:13
09/20/17
09/20
14:13
09/20/17
14:13
Technical Analysis
Technical View: S&P 500 slips below the pivot low »

The S&P 500 (SPX) is…

SPY

SPDR S&P 500 ETF Trust

$249.89

-0.08 (-0.03%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZRX

PhaseRx

$0.78

0.055 (7.64%)

14:11
09/20/17
09/20
14:11
09/20/17
14:11
Hot Stocks
PhaseRx confirms receipt of FDA orphan drug designation for PRX-ASL »

PhaseRx announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$49.34

0.24 (0.49%)

14:10
09/20/17
09/20
14:10
09/20/17
14:10
Hot Stocks
Sanofi reports 'potential breakthrough' in preclinical work on HIV antibodies »

Researchers working…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

SPX

S&P 500

14:06
09/20/17
09/20
14:06
09/20/17
14:06
General news
Fed details plans to being reducing balance sheet »

The Federal Reserve said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$14.06

0.29 (2.11%)

14:05
09/20/17
09/20
14:05
09/20/17
14:05
Options
Valeant call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Oct

SPY

SPDR S&P 500 ETF Trust

$249.87

-0.1 (-0.04%)

, SPX

S&P 500

14:04
09/20/17
09/20
14:04
09/20/17
14:04
General news
Federal Reserve maintains median projection for year-end funds rate at 1.4% »

The Fed's "dot…

SPY

SPDR S&P 500 ETF Trust

$249.87

-0.1 (-0.04%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

14:02
09/20/17
09/20
14:02
09/20/17
14:02
General news
Fed says economic activity rising moderately this year »

The Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$68.25

-0.24 (-0.35%)

, SYMC

Symantec

$34.16

0.39 (1.15%)

14:02
09/20/17
09/20
14:02
09/20/17
14:02
Periodicals
Breaking Periodicals news story on Splunk, Symantec »

Symantec 'play'…

SPLK

Splunk

$68.25

-0.24 (-0.35%)

SYMC

Symantec

$34.16

0.39 (1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

SPX

S&P 500

14:01
09/20/17
09/20
14:01
09/20/17
14:01
General news
Fed plans to initiate balance sheet normalization in October »

The Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:01
09/20/17
09/20
14:01
09/20/17
14:01
General news
FOMC Meeting Announcement Federal Funds Rate data reported »

FOMC Meeting Announcement…

14:00
09/20/17
09/20
14:00
09/20/17
14:00
General news
Breaking General news story  »

Federal Reserve leaves…

RNVA

Rennova Health

$0.22

-0.0021 (-0.93%)

13:55
09/20/17
09/20
13:55
09/20/17
13:55
Conference/Events
Rennova Health to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MLCO

Melco Resorts & Entertainment

$23.78

0.77 (3.35%)

13:50
09/20/17
09/20
13:50
09/20/17
13:50
Options
Bullish option play opened in Melco Resorts as shares tick to 52-week highs »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

MOH

Molina Healthcare

$62.33

0.21 (0.34%)

, UNH

UnitedHealth

$195.34

0.69 (0.35%)

13:48
09/20/17
09/20
13:48
09/20/17
13:48
Periodicals
McConnell intends to consider healthcare bill in Senate next week, WSJ says »

A spokesman for Senate…

MOH

Molina Healthcare

$62.33

0.21 (0.34%)

UNH

UnitedHealth

$195.34

0.69 (0.35%)

CNC

Centene

$90.10

0.32 (0.36%)

WCG

WellCare

$166.10

-2.065 (-1.23%)

CI

Cigna

$181.44

-0.07 (-0.04%)

ANTM

Anthem

$181.90

0.46 (0.25%)

HNT

Health Net

HUM

Humana

$238.58

-1.46 (-0.61%)

AET

Aetna

$154.56

-1.48 (-0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

  • 08

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.